icotyde psoriasis - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,833 +0.73%

DJIA 48,280 +0.77%

Nasdaq 25,073 +0.72%

DAX 23,901 -0.26%

Gold $4,196 +0.16%

Oil $98.10 +1.46%

BTC $72,062 +0.97%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,217 +0.37%

S&P 500 6,833 +0.73%

DJIA 48,280 +0.77%

Nasdaq 25,073 +0.72%

DAX 23,901 -0.26%

Gold $4,196 +0.16%

Oil $98.10 +1.46%

BTC $72,062 +0.97%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,217 +0.37%

icotyde psoriasis

Johnson & Johnson FDA approval ICOTYDE oral IL‑23R psoriasis pill in premium product close-up

Pharma & Healthcare·Stocks·USA

Johnson & Johnson FDA approval ICOTYDE Boom Explained

By Maik Kemper • Mar 18, 2026

Johnson & Johnson FDA approval ICOTYDE oral IL‑23R psoriasis pill in premium product close-up

Pharma & Healthcare·Stocks·USA

Johnson & Johnson FDA approval ICOTYDE Boom Explained

By Maik Kemper • Mar 18, 2026

Can Johnson & Johnson’s FDA approval of ICOTYDE really shift the psoriasis market enough to move a $575 billion healthcare giant? Maik Kemper Editor in…